Theravance Biopharma, Inc. Overview
Pro stress-test →Theravance Biopharma is a biopharmaceutical company primarily focused on the development and commercialization of medicines for specialty respiratory and neurologic diseases. The company operates a streamlined portfolio centered on YUPELRI, a once-daily nebulized long-acting muscarinic antagonist for COPD treatment, and is advancing Ampreloxetine, a late-stage norepinephrine reuptake inhibitor for symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy.
Strategic Profile
Pro stress-test →The company maintains a robust pipeline, fortress-like balance sheet, and focus on addressing Multiple System Atrophy (MSA). Theravance has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI, providing diversified revenue streams and reduced development risk.
Competitive Landscape
Pro stress-test →Theravance competes in specialty respiratory and neurologic disease markets. The COPD segment faces competition from established respiratory players (Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca), while the MSA/nOH segment remains less crowded with higher unmet medical need. The company's partnership model with Viatris reduces direct competitive pressure on YUPELRI commercialization.
Industry Context
Theravance Biopharma, Inc. operates in Biopharmaceuticals - Specialty Respiratory & Rare Neurologic Diseases.
Key facts
Founded: 2013 · Headquarters: South San Francisco, CA / George Town, KY · Employees: 97 · Revenue: $64.4M · Market cap: $965.8M